A First-in-human Study of YN001 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 16, 2022

Primary Completion Date

August 9, 2024

Study Completion Date

August 9, 2024

Conditions

Cardiovascular Diseases

Interventions

DRUG

YN001

Dose ranges from 2-90mg

DRUG

Placebo for YN001

5% dextrose injection to mimic the YN001

Trial Locations (1)

Nucleus Network Pty Ltd, Melbourne

All Listed Sponsors

lead

Beijing Inno Medicine Co., Ltd.

INDUSTRY